Singapúr - enska - HSA (Health Sciences Authority)

orion pharma (sg) pte. ltd. - beclomethasone dipropionate (micronized) - powder, metered - 200mcg/metered dose - beclomethasone dipropionate (micronized) 200mcg/metered dose

Kanada - enska - Health Canada

bausch health, canada inc. - beclomethasone dipropionate - cream - 0.025% - beclomethasone dipropionate 0.025% - anti-inflammatory agents

Malasía - enska - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

orion pharma (my) sdn. bhd. - beclomethasone dipropionate -

Malasía - enska - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

glenmark pharmaceuticals (malaysia) sdn. bhd. - beclomethasone dipropionate; clotrimazole -

Kenía - enska - Pharmacy and Poisons Board

glenmark pharmaceuticals limited glenmark house, hdo-corporate building, wing – a, - beclomethasone dipropionate anhydrous ep - inhalation vapour - each actuation delivers: beclomethasone… - other drugs for obstructive airway diseases

Kenía - enska - Pharmacy and Poisons Board

glenmark pharmaceuticals limited glenmark house, hdo-corporate building, wing – a, - beclomethasone dipropionate anhydrous ep - inhalation vapour, liquid - each actuation delivers: beclomethasone… - other drugs for obstructive airway diseases

Írland - enska - HPRA (Health Products Regulatory Authority)

norton waterford - beclometasone dipropionate - pressurised inhalation suspension

Írland - enska - HPRA (Health Products Regulatory Authority)

norton waterford - beclometasone dipropionate - pressurised inhalation suspension

Írland - enska - HPRA (Health Products Regulatory Authority)

norton waterford - beclometasone dipropionate - pressurised inhalation suspension

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - beclometasone dipropionate, quantity: 100 microgram; formoterol fumarate dihydrate, quantity: 6 microgram - inhalation, pressurised - excipient ingredients: norflurane; ethanol absolute; hydrochloric acid - asthma fostair is indicated in adults (18 years and older) in the treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate: - patients not adequately controlled with inhaled corticosteroids (ics) and 'as needed' inhaled rapid-acting beta2-agonist or - patients already adequately controlled on both ics and long-acting beta2-agonists (laba). (see section 4.2 dose and method of administration for treatment approaches). copd (fostair 100/6 only) symptomatic treatment of adults with severe copd (fev1 less than 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.